Capecitabine + Pembrolizumab

Phase 2UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Estrogen Receptor Negative

Conditions

Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma

Trial Timeline

May 25, 2017 → May 1, 2021

NCT ID

NCT03044730

About Capecitabine + Pembrolizumab

Capecitabine + Pembrolizumab is a phase 2 stage product being developed by Merck for Estrogen Receptor Negative. The current trial status is unknown. This product is registered under clinical trial identifier NCT03044730. Target conditions include Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative.

What happened to similar drugs?

1 of 3 similar drugs in Estrogen Receptor Negative were approved

Approved (1) Terminated (0) Active (2)

✅RAD001 + ExemestaneNovartisApproved

🔄Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH AgonistRochePhase 3

🔄Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH AgonistRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03044730	Phase 2	UNKNOWN	May 25, 2017	May 1, 2021	Estrogen Receptor Negative

Competing Products

20 competing products in Estrogen Receptor Negative

See all competitors

Product	Company	Stage	Hype Score
Palbociclib (75, 100, 125 milligram [mg]) + H3B-6545 (150, 300, 450 mg)	Eisai	Phase 1	33
eribulin mesylate + capecitabine	Eisai	Phase 2	35
eribulin mesylate + carboplatin	Eisai	Phase 2	31
AZD2014 + Everolimus + Fulvestrant	AstraZeneca	Phase 2	35
AZD5363 + Placebo + Fulvestrant	AstraZeneca	Phase 1/2	36
Carboplatin + Pembrolizumab	Merck	Phase 2	42
Pembrolizumab + Cisplatin	Merck	Phase 2	27
Anastrozole + Doxorubicin Hydrochloride + Exemestane + Letrozole + Pembrolizumab	Merck	Phase 2	35
everolimus + anastrozole + letrozole + tamoxifen citrate + fulvestrant + megestrol acetate	Novartis	Phase 2	27
Everolimus	Novartis	Phase 2	27
RAD001 + Exemestane	Novartis	Approved	43
Venetoclax + Fulvestrant	Roche	Phase 2	27
Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH Agonist	Roche	Phase 3	44
Giredestrant + Fulvestrant or an Aromatase Inhibitor (Physician Choice) + LHRH Agonist	Roche	Phase 2	39
Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH Agonist	Roche	Phase 3	47
GS-5829 + Exemestane + Fulvestrant	Gilead Sciences	Phase 1/2	24
conjugated estrogens/progestin (MPA)	Pfizer	Phase 1	29
INIPARIB + irinotecan	Sanofi	Phase 2	35
Copanlisib + Letrozole + Palbociclib	Bayer	Phase 1	18
entinostat + anastrozole	Syndax Pharmaceuticals	Phase 2	21